Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Malonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.75 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.75 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | CTH | P32929 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL9240906 | 1.00 | LDHA (0.75) | LDHASRRFFAR3LCKFYN | |
| Malonic Acid SCHEMBL28539575 | 1.00 | LDHA (0.75) | LDHASRRFFAR3LCKFYN | |
| Malonic Acid SCHEMBL11075854 | 0.96 | LDHA (0.69) | LDHASRRFFAR3LCKFYN | |
| Malonic Acid SCHEMBL27656392 | 0.92 | LDHA (0.75) | LDHASRRFFAR3LCKFYN | |
| Malonic Acid SCHEMBL27706336 | 0.89 | LDHA (0.60) | LDHASRRFFAR3LCKFYN | |
| Malonic Acid SCHEMBL3608474 | 0.87 | — | — | |
| Malonic Acid SCHEMBL782125 | 0.87 | — | — | |
| Malonic Acid SCHEMBL3358611 | 0.87 | — | — | |
| Malonic Acid SCHEMBL1332405 | 0.87 | — | — | |
| Malonic Acid SCHEMBL1332554 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116930284-A | Biosensor | 爱科来株式会社 | 2023-10-24 | — | — | CN | disclosed |
| CN-116930285-A | Biosensor and method for manufacturing biosensor | 爱科来株式会社 | 2023-10-24 | — | — | CN | disclosed |
| US-20220105066-A1 | Antidotes to Cyanide Poisoning | THE GENERAL HOSPITAL CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-20220023254-A1 | ANTI-VIRAL COMPOUND | BYOTROL LIMITED (GB) | 2022-01-27 | — | — | US | disclosed |
| CN-104906139-B | Enhancement of allogeneic hematopoietic stem cell transplantation | 小利兰·斯坦福大学托管委员会 | 2020-10-23 | — | — | CN | disclosed |
| US-20200276148-A1 | Antidotes to Cyanide Poisoning | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| EP-3609479-A1 | ANTIDOTES TO CYANIDE POISONING | The General Hospital Corporation (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-110290860-A | Thin film covalently bonded to cellulose ester film and method for producing same | 梵特斯技术有限公司 | 2019-09-27 | — | — | CN | disclosed |
| WO-2018191537-A1 | ANTIDOTES TO CYANIDE POISONING | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-18 | — | — | WO | disclosed |
| CN-105523979-A | Azothiourea anion receptor and preparation method and application thereof | UNIV JIANGHAN | 2016-04-27 | — | — | CN | disclosed |
| CN-101591073-A | Phosphate-free corrosion inhibition antisludging agent and preparation method | ZHEJIANG ASING ENVIRONMENTAL T (CN) | 2009-12-02 | — | — | CN | disclosed |
| EP-1765324-A4 | COMPOSITIONS OF STABLE BIOACTIVE METABOLITES OF DOCOSAHEXAENOIC (DHA) AND EICOSAPENTAENOIC (EPA) ACIDS | NATREON INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1765324-A2 | COMPOSITIONS OF STABLE BIOACTIVE METABOLITES OF DOCOSAHEXAENOIC (DHA) AND EICOSAPENTAENOIC (EPA) ACIDS | Natreon Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006007310-A2 | COMPOSITIONS OF STABLE BIOACTIVE METABOLITES OF DOCOSAHEXAENOIC (DHA) AND EICOSAPENTAENOIC (EPA) ACIDS | NATREON INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20050282781-A1 | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids | NATREON INC. | 2005-12-22 | — | — | US | disclosed |
| US-6242481-B1 | ADMINISTERING CYTOCHALASIN DERIVATIVE AS ANTICARCINOGENIC OR ANTITUMOR AGENT | THE CHILDREN'S MEDICAL CENTER CORP. | 2001-06-05 | — | — | US | disclosed |
| US-5994388-A | Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1998041205-A1 | CYTOCHALASIN AND ISOINDOLINONE DERIVATIVES AS INHIBITORS OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-09-24 | — | — | WO | disclosed |
| US-5693327-A | PLANT EXTRACTS FROM MELIA AZADIRACHTA AND CENTRATHERUM ANTHELMINTHICUM; ECZEMA TREATMENT | SHAH ELADEVI (GB) | 1997-12-02 | — | — | US | disclosed |
| EP-0310125-B1 | Silver halide color photographic material | FUJI PHOTO FILM CO LTD (JP) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023254-A1 | ANTI-VIRAL COMPOUND | RPL35, ALG8, EIF2AK2 | LDHA 1292/4885SRR 3873/4885FFAR3 4710/4885 |
| US-20200276148-A1 | Antidotes to Cyanide Poisoning | OAT, CAT, ABCB7 | LDHA 232/4885SRR 1762/4885FFAR3 4810/4885 |
| US-20050282781-A1 | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids | ALOX15, ALOX12, BDKRB2 | LDHA 2920/4885SRR 325/4885FFAR3 187/4885 |
| US-20220105066-A1 | Antidotes to Cyanide Poisoning | OAT, CAT, ABCB7 | LDHA 232/4885SRR 1762/4885FFAR3 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.